Edition:
United States

Express Scripts Holding Co (ESRX.O)

ESRX.O on Nasdaq

75.85USD
7 Dec 2016
Change (% chg)

$-0.88 (-1.15%)
Prev Close
$76.73
Open
$75.50
Day's High
$76.38
Day's Low
$74.47
Volume
3,840,300
Avg. Vol
3,739,223
52-wk High
$89.00
52-wk Low
$64.46

Latest Key Developments (Source: Significant Developments)

Express Scripts Q3 earnings per share $1.15
Tuesday, 25 Oct 2016 04:01pm EDT 

Express Scripts Holding Co - : Express Scripts announces 2016 third quarter results . Narrowed its 2016 earnings per diluted share guidance from a range of $4.45 to $4.55 to a range of $4.47 to $4.53 . Q3 earnings per share $1.15 . Q3 earnings per share view $1.74 -- Thomson Reuters I/B/E/S . Sees Q4 2016 adjusted earnings per share $1.84 to $1.90 . Sees FY 2016 adjusted earnings per share $6.36 to $6.42 . Sees FY 2016 earnings per share $4.47 to $4.53 . Sees Q4 2016 earnings per share $1.38 to $1.44 . Qtrly adjusted claims of 312.2 million, down 5% . Expects total adjusted claims for Q4 of 2016 to be in range of 314 million to 329 million . Express scripts holding co is increasing its expected 2017 retention rate for 2016 selling season to a range of 97% - 98% . Qtrly revenues $25.41 billion versus $ 25.22 billion . Sees FY total adjusted claims 1,265 million to 1,280 million .Q3 revenue view $25.49 billion -- Thomson Reuters I/B/E/S.  Full Article

Express Scripts chief medical officer says Mylan has a monopoly on the EpiPen
Thursday, 25 Aug 2016 04:03pm EDT 

: Express Scripts Chief Medical Officer Steve Miller On Mylan Epipen Price Hike - "Mylan could lower the price today" . Express Scripts Chief Medical Officer Steve Miller On Mylan Epipen Price Hike - Mylan has a monopoly on the epipen Further company coverage: [MYL.O ESRX.O] ((Bangalore.newsroom@thomsonreuters.com;)).  Full Article

Horizon pharma says it continues to have discussions with Express Scripts
Monday, 1 Aug 2016 09:01pm EDT 

Horizon Pharma : Continues to have discussions with express scripts and sees potential pathway to completion of potential partnership with express scripts beginning 2017 .Recognizes express scripts published formulary exclusion list, which will take effect on january 1, 2017, includes duexis and vimovo.  Full Article

Horizon pharma says it continues to have discussions with Express Scripts
Monday, 1 Aug 2016 03:56pm EDT 

Horizon Pharma : Continues to have discussions with express scripts and sees potential pathway to completion of potential partnership with express scripts beginning 2017 .Recognizes express scripts published formulary exclusion list, which will take effect on january 1, 2017, includes duexis and vimovo.  Full Article

Express Scripts Q2 earnings per share $1.13
Monday, 25 Jul 2016 04:59pm EDT 

Express Scripts Holding Co : Says Q2 revenue $25.22 billion versus $25.45 billion . Sees Q3 total adjusted claims 311 million to 321 million . Year adjusted diluted eps guidance range; raises mid-point; provides 2016 third quarter guidance . Q2 earnings per share $1.13 . Q2 earnings per share view $1.57 -- Thomson Reuters I/B/E/S . Sees FY 2016 adjusted earnings per share $6.33 to $6.43 . Q2 adjusted earnings per share $1.57 . Says Q2 adjusted claims of 315.3 million . Says narrows 2016 adjusted earnings per diluted share guidance to a range of $6.33 to $6.43 . Sees Q3 adjusted diluted earnings per share $1.72 to $1.76 .FY 2016 earnings per share view $6.35; q3 earnings per share view $1.72 -- Thomson Reuters I/B/E/S.  Full Article

Express Scripts Holding Co increases authorization for share repurchase program
Thursday, 3 Dec 2015 04:01pm EST 

Express Scripts Holding Co:Increases authorization for share repurchase program.Approved increase in number of shares that may be repurchased under share repurchase program by 60 million shares.  Full Article

Express Scripts Holding Co raises FY 2015 EPS guidance
Tuesday, 27 Oct 2015 04:01pm EDT 

Express Scripts Holding Co:Raised and narrowed its FY 2015 adjusted diluted earnings per share guidance from a range of $5.46 to $5.54 to a range of $5.51 to $5.55, which represents growth of 13% to 14% over FY 2014.FY 2015 EPS of $5.50 - Thomson Reuters I/B/E/S.  Full Article

Express Scripts Holding Co names Eric Slusser as CFO
Thursday, 10 Sep 2015 04:30pm EDT 

Express Scripts Holding Co:Says Eric Slusser appointed CFO.Says Slusser was most recently chief financial officer of gentiva health services inc.Jim Havel, former interim chief financial officer, will continue with Express Scripts as executive vice president of Finance.  Full Article

Express Scripts Holding Co announces CEO change
Wednesday, 9 Sep 2015 04:30pm EDT 

Express Scripts Holding Co:Names tim wentworth chief executive officer, effective May 2016; George paz to retire and remain as chairman.Says CEO George Paz to retire.Paz will remain on board as non-executive chairman following his retirement.Says thomas mac mahon will continue as lead independent director.Paz will retire as CEO, effective following co's annual meeting of stockholders currently scheduled for May 2016.  Full Article

Express Scripts Holding Co raises FY 2015 EPS guidance
Tuesday, 28 Jul 2015 04:10pm EDT 

Express Scripts Holding Co:Increases FY 2015 adjusted earnings per diluted share guidance from a range of $5.37 to $5.47 to a range of $5.46 to $5.54, which raises the mid-point from $5.42 to $5.50.FY 2015 EPS of $5.44 - Thomson Reuters I/B/E/S.  Full Article

Fitch Assigns First-Time 'BB-' Rating to MedImpact; Outlook Positive

(The following statement was released by the rating agency) CHICAGO, November 18 (Fitch) Fitch Ratings has assigned a 'BB-' Issuer Default Rating to MedImpact Holdings, Inc. and its issuing subsidiary, MI OpCo Holdings, Inc. The Rating Outlook is Positive. A full list of rating actions follows at the end of this release. KEY RATING DRIVERS Smaller Scale in Consolidated Industry: MedImpact is a top-5 pharmacy benefit manager (PBM) but is significantly smaller than its three largest competitor